Peer-influenced content. Sources you trust. No registration required. This is HCN.

OBR OncologyToxicity From Sotorasib-Immunotherapy Combo Leads to New Approach

Results from the phase 1b CodeBreak 100/1 trial show that administering the novel KRAS
inhibitor sotorasib alone prior to combining it with an immune checkpoint inhibitor led to
lower rates of grade 3-4 treatment-related adverse events compared with beginning
administration of the treatments concurrently.